Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 147-154

  Mittal, Ankit ^a   Schulze, Kai ^c   Ebensen, Thomas ^c   Weißmann, Sebastian ^c   Hansen, Steffi ^a,b   Lehr, Claus Michael ^a,b   Guzmán, Carlos A ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Chitosan PLGA nanoparticles; Ovalbumin; Transfollicular; Vaccination

Indexed keywords

ANTIGENS; CHITOSAN; COPOLYMERS; NANOPARTICLES; VACCINES;

ADENOSINE MONOPHOSPHATE; IMMUNE RESPONSE; OVALBUMINS; PLGA NANOPARTICLES; POLY LACTIC-CO-GLYCOLIC ACID; TRANSCUTANEOUS VACCINATIONS; TRANSFOLLICULAR; VACCINATION;

IMMUNE SYSTEM;

ADENOSINE PHOSPHATE; ADJUVANT; ANTIGEN; BIS (3',5') CYCLIC DIMERIC ADENOSINE MONOPHOSPHATE; CHITOSAN; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; UNCLASSIFIED DRUG; VACCINE; CYTOKINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HAIR FOLLICLE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEEDLE FREE TRANSCUTANEOUS VACCINATION; NONHUMAN; SKIN; VACCINATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; NANOMEDICINE; NEEDLE; PROCEDURES; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS; CELL PROLIFERATION; CHITOSAN; CYTOKINES; DRUG CARRIERS; FEMALE; IMMUNITY, HUMORAL; LACTIC ACID; MICE; MICE, INBRED C57BL; NANOMEDICINE; NANOPARTICLES; NEEDLES; OVALBUMIN; POLYGLYCOLIC ACID; T-LYMPHOCYTES; VACCINATION;

EID: 84919625484     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.009     Document Type: Article

References (33)

1. Karande P., Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol Eng 2010, 1:175-201.
2. Bal S.M., Ding Z., van Riet E., Jiskoot W., Bouwstra J.A. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?. J Control Release 2010, 148:266-282.
3. Fan H., Lin Q., Morrissey G.R., Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999, 17:870-872.
4. Lademann J., Richter H., Teichmann A., Otberg N., Blume-Peytavi U., Luengo J., et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm 2007, 66:159-164.
5. Mittal A., Raber A.S., Schaefer U.F., Weissmann S., Ebensen T., Schulze K., et al. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 2013, 31:3442-3451.
6. Mahe B., Vogt A., Liard C., Duffy D., Abadie V., Bonduelle O., et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009, 129:1156-1164.
7. Shaker D.S., Sloat B.R., Le U.M., Löhr C.V., Yanasarn N., Fischer K.A., et al. Immunization by application of DNA vaccine onto a skin area wherein the hair follicles have been induced into anagen-onset stage. Mol Ther 2007, 15:2037-2043.
8. Xiao G., Li X., Kumar A., Cui Z. Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses. Eur J Pharm Biopharm 2012, 82:212-217.
9. Elias P.M., Menon G.K. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991, 24:1-26.
10. Ebensen T., Libanova R., Schulze K., Yevsa T., Morr M., Guzmán C.A. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 2011, 29:5210-5220.
11. Netzlaff F., Kostka K.H., Lehr C.M., Schaefer U.F. TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. Eur J Pharm Biopharm 2006, 63:44-50.
12. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
13. Liard C., Munier S., Arias M., Joulin-Giet A., Bonduelle O., Duffy D., et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 2011, 29:6379-6391.
14. Li N., Peng L.-H., Chen X., Zhang T.-Y., Shao G.-F., Liang W.-Q., et al. Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization. Nanomedicine 2014, 10(1):215-223.
15. Rancan F., Amselgruber S., Hadam S., Munier S., Pavot V., Verrier B., et al. Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells. J Control Release 2014, 176(1):115-122.
16. Kugelberg E., Norström T., Petersen T.K., Duvold T., Andersson D.I., Hughes D. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 2005, 49:3435-3441.
17. Wanke I., Skabytska Y., Kraft B., Peschel A., Biedermann T., Schittek B. Staphylococcus aureus skin colonization is promoted by barrier disruption and leads to local inflammation. Exp Dermatol 2013, 22:153-155.
18. Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C.D., Avgoustakis K. Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses. Int J Pharm 2010, 385:187-193.
19. Li N., Peng L.H., Chen X., Nakagawa S., Gao J.Q. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo. Int J Nanomedicine 2011, 6:3241-3250.
20. Sen D., Forrest L., Kepler T.B., Parker I., Cahalan M.D. Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1- and Th2-polarizing adjuvants. Proc Natl Acad Sci U S A 2010, 107:8334-8339.
21. Inoue J., Yotsumoto S., Sakamoto T., Tsuchiya S., Aramaki Y. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice. J Control Release 2005, 108:294-305.
22. Kahlon R., Hu Y., Orteu C.H., Kifayet A., Trudeau J.D., Tan R., Dutz J.P. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 2003, 21:2890-2899.
23. Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013, 161(Suppl. 2):3-9.
24. Shi H.Z. Eosinophils function as antigen-presenting cells. J Leukoc Biol 2004, 76:520-527.
25. Spencer L.A., Weller P.F. Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol 2010, 88:250-256.
26. MacKenzie J.R., Mattes J., Dent L.A., Foster P.S. Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J Immunol 2001, 167:3146-3155.
27. Roth N., Städler S., Lemann M., Hösli S., Simon H.-U., Simon D. Distinct eosinophil cytokine expression patterns in skin diseases-the possible existence of functionally different eosinophil subpopulations. Allergy 2011, 66:1477-1486.
28. Zimmerli S.C., Harari A., Cellerai C., Vallelian F., Bart P.-A., Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 2005, 102:7239-7244.
29. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 gag-specific IFN-gamma+IL-2(+) and CD28(+)IL-2(+) CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002, 169:6376-6385.
30. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8(+) T cells. Blood 2006, 107:4781-4789.
31. Williams M.A., Tyznik A.J., Bevan M.J. Interleukin-2 signals during priming are required for secondary expansion of CD8(+) memory T cells. Nature 2006, 441:890-893.
32. Morrison S.G., Su H., Caldwell H.D., Morrison R.P. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun 2000, 68:6979-6987.
33. Kaveh D.A., Bachy V.S., Hewinson R.G., Hogarth P.J. Systemic BCG immunization induces persistent lung mucosal multifunctional CD4 T-EM cells which expand following virulent mycobacterial challenge. PLoS One 2011, 6.